National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
Topics
- Alcohol Use (1)
- COVID-19 (1)
- Healthcare Costs (1)
- Health Services Research (HSR) (1)
- Hospitalization (1)
- (-) Human Immunodeficiency Virus (HIV) (5)
- Infectious Diseases (1)
- Opioids (1)
- Prevention (3)
- (-) Public Health (5)
- Racial and Ethnic Minorities (1)
- Screening (2)
- Social Stigma (1)
- Substance Abuse (1)
- Vaccination (1)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 5 of 5 Research Studies DisplayedZubiago J, Murphy M, Guardado R
Increased HIV testing in people who use drugs hospitalized in the first wave of the COVID-19 pandemic.
During the COVID-19 pandemic, due to lapses in harm reduction services, several public health experts forecasted subsequent increases in diagnosis of HIV in PWUD. As many inpatient hospitals reworked patient flow during the COVID-19 surge, the investigators hypothesized that HIV testing in PWUD would decrease. To answer this question, they compiled a deidentified list of hospitalized patients with electronic medical record indicators of substance use-a positive urine toxicology screen, prescribed medications to treat opioid use disorder, a positive CIWA score, or a positive CAGE score-admitted between January, 2020 and August, 2020.
AHRQ-funded; HS026008.
Citation: Zubiago J, Murphy M, Guardado R .
Increased HIV testing in people who use drugs hospitalized in the first wave of the COVID-19 pandemic.
J Subst Abuse Treat 2021 May;124:108266. doi: 10.1016/j.jsat.2020.108266..
Keywords: Human Immunodeficiency Virus (HIV), Opioids, Substance Abuse, Alcohol Use, Hospitalization, COVID-19, Public Health, Screening
Brault MA, Spiegelman D, Hargreaves J
Treatment as prevention: concepts and challenges for reducing HIV incidence.
This paper reviews the results and lessons learned from four large-scale HIV antiretroviral therapy (ART) clinical trials that were held in sub-Saharan Africa to reduce HIV transmission. These trials used treatment as prevention (TasP) to improve overall health and protect HIV-uninfected sexual partners from infection. There were seemingly inconsistent findings in the major TasP trials held in South African, Kenya, Uganda, Botswana, and Zambia. The review highlighted implementation challenges and identified approaches to optimize programs and incentivize uptake and engagement in HIV testing and ART-based care.
AHRQ-funded; HS023000.
Citation: Brault MA, Spiegelman D, Hargreaves J .
Treatment as prevention: concepts and challenges for reducing HIV incidence.
J Acquir Immune Defic Syndr 2019 Dec 1;82 Suppl 2:S104-s12. doi: 10.1097/qai.0000000000002168..
Keywords: Human Immunodeficiency Virus (HIV), Prevention, Infectious Diseases, Public Health, Screening
de Montigny S, Adamson BJS, Masse BR
Projected effectiveness and added value of HIV vaccination campaigns in South Africa: a modeling study.
Sci Rep 2018 Apr 17;8(1):6066. doi: 10.1038/s41598-018-24268-4.
In this paper, the authors estimated the potential epidemiological and economic impact of HIV vaccine campaigns compared to continuous vaccination, assuming that vaccine efficacy was transient and dependent on immune response. The investigators concluded that results suggested a partially effective HIV vaccine would have substantial impact on the HIV epidemic in South Africa and offer good value if priced less than $105 for a five-dose series. They suggested that vaccination campaigns every two years may offer greater value for money than continuous vaccination reaching the same coverage level.
In this paper, the authors estimated the potential epidemiological and economic impact of HIV vaccine campaigns compared to continuous vaccination, assuming that vaccine efficacy was transient and dependent on immune response. The investigators concluded that results suggested a partially effective HIV vaccine would have substantial impact on the HIV epidemic in South Africa and offer good value if priced less than $105 for a five-dose series. They suggested that vaccination campaigns every two years may offer greater value for money than continuous vaccination reaching the same coverage level.
AHRQ-funded; HS013853.
Citation: de Montigny S, Adamson BJS, Masse BR .
Projected effectiveness and added value of HIV vaccination campaigns in South Africa: a modeling study.
Sci Rep 2018 Apr 17;8(1):6066. doi: 10.1038/s41598-018-24268-4..
Keywords: Health Services Research (HSR), Healthcare Costs, Human Immunodeficiency Virus (HIV), Public Health, Vaccination
Nikolopoulos GK, Pavlitina E, Muth SQ
A network intervention that locates and intervenes with recently HIV-infected persons: the Transmission Reduction Intervention Project (TRIP).
The Transmission Reduction Intervention Project (TRIP) evaluated a network intervention to detect individuals infected with HIV within the past 6 months. Results indicated that strategic network tracing that starts with recently infected persons could support public health efforts to find and treat people early in their HIV infection.
AHRQ-funded; HS000084.
Citation: Nikolopoulos GK, Pavlitina E, Muth SQ .
A network intervention that locates and intervenes with recently HIV-infected persons: the Transmission Reduction Intervention Project (TRIP).
Sci Rep 2016 Dec 5;6:38100. doi: 10.1038/srep38100.
.
.
Keywords: Human Immunodeficiency Virus (HIV), Prevention, Public Health
Calabrese SK, Underhill K, Earnshaw VA
Framing HIV Pre-Exposure Prophylaxis (PrEP) for the general public: How inclusive messaging may prevent prejudice from diminishing public support.
The authors examined how public attitudes toward HIV pre-exposure prophylaxis (PrEP) differed based on the social group PrEP was described as benefiting and the moderating effect of prejudice. They found a disparity in support that was stronger among participants reporting greater prejudice and concluded that inclusive framing of PrEP in public discourse may prevent prejudice from undermining implementation efforts.
AHRQ-funded; HS022986.
Citation: Calabrese SK, Underhill K, Earnshaw VA .
Framing HIV Pre-Exposure Prophylaxis (PrEP) for the general public: How inclusive messaging may prevent prejudice from diminishing public support.
AIDS Behav 2016 Jul;20(7):1499-513. doi: 10.1007/s10461-016-1318-9.
.
.
Keywords: Human Immunodeficiency Virus (HIV), Prevention, Public Health, Racial and Ethnic Minorities, Social Stigma